| Part of a series on |
| Psychedelia |
|---|
 |
 | This article needs more reliable medical references for verification or relies too heavily on primary sources. (November 2020) |  |
Psychedelic microdosing involves consuming sub-threshold doses (microdoses) of serotonergic psychedelic drugs like LSD and psilocybin to potentially enhance creativity, energy, emotional balance, problem-solving abilities, and to address anxiety, depression,[1] and addiction.[2][3] This practice has gained popularity in the 21st century.[4][5] A June 2024 report by the RAND Corporation suggests that among adults in the United States reporting the use of psilocybin in the past year, nearly half reported microdosing the last time they used it.[6]
- ^ MindBio Therapeutics (2024-08-19). "MindBio Announces Sustained Antidepressant Response 3-Months Post Treatment in Microdosing Depression Clinical Trials". Accesswire.
- ^ Fadiman J (January 2016). "Microdose research: without approvals, control groups, double blinds, staff or funding". Psychedelic Press. XV.
- ^ Brodwin E (30 January 2017). "The truth about 'microdosing,' which involves taking tiny amounts of psychedelics like LSD". Business Insider. Retrieved 19 April 2017.
- ^ Dahl H (7 July 2015). "A Brief History of LSD in the Twenty-First Century". Psychedelic Press UK. Retrieved 19 April 2017.
- ^ Ellwood B (2020-10-28). "International study finds 79% of individuals who microdose with psychedelics report improvements in their mental health". PsyPost. Retrieved 2023-10-09.
- ^ Kilmer B, Priest M, Ramchand R, Rogers RC, Senator B, Palmer K (2024-06-27). Considering Alternatives to Psychedelic Drug Prohibition (Report). RAND Corporation.